top of page

Pediatric Cardio-Oncology Webinars

Welcome to the Pediatric Cardio-Oncology Webinar series, sponsored by Sofia's Hope and hosted by Heart University at Cincinnati Children's.  These webinars were held leading up to the 1st International Pediatric Cardio-Oncology Conference slated for October 21- 22, 2022.

August 24, 2022

A Dex of Cards: Shuffling Through 2022

Moderator:  Steven Lipshultz, MD

University at Buffalo Jacobs School of
Medicine and Biomedical Sciences;
John R. Oishei Children‘s Hospital

Joseph R Carver, MD

Seattle Children’s Hospital
Anthracyclines and Dexrazoxane: mechanisms and issue


Elvira van Dalen, MD, PhD

Princess Maxima Center
Dexrazoxane Guidelines


Eric J Chow, MD, MPH

Seattle Children’s
Long-term safety and efficacy of dexrazoxane in pediatric cancer patients

April 12, 2022

A Pediatric Oncologist and Pediatric Cardiologist Walk Into a Bar… Discussions of Interesting and Perplexing Patients Between Colleagues


Kasey Ledger, MD, MSc

Seattle Children’s Hospital

Cancer and Blood Disorders


Thomas D. Ryan, MD, PhD

Cincinnati Children’s Hospital

Heart Institute


Juli Sublet, MSN, APRN-FNP

Cincinnati Children’s Hospital

December 14, 2021

The Role of Risk Prediction Models in Guiding Cardio-Oncology Care


Moderator - Melissa Hudson, MD from St. Jude's Children's Research Hospital 


Eric Chow, MD, MPH at Seattle Children's Hospital:  Individual Prediction of Heart Failure Among Childhood Cancer Survivors


Jennifer Yeh, PhD at Boston Children's Hospital:  Cost-effectiveness of Routine Echocardiography Screening for Asymptomatic Left Ventricular Dysfunction


Jan Leerink - PhD Candidate at Princess Maxima Centrum:  Refining the 10-Year Prediction of Left Ventricular Systolic Dysfunction

August 26, 2021
The Pharmacogenetics of Anthracycline-Related Cardiomyopathy in Survivors of Pediatric Cancers

Moderator - Greg Armstrong, MD, MSCE from St. Jude Children’s Research Hospital. 


Myocardial Determinants for the Metabolism and Toxicity of Anthracycline Drugs  by Javier Blanco, PhD, Professor of Pharmacology at University of Buffalo

The Pharmacogenetics of Anthracycline-Related Cardiomyopathy in Survivors of Pediatric Cancers by Smita Bhatia, MD and Director of Institute for Cancer Outcomes and Survivorship at UAB


The Role of the Genome in Doxorubicin-Induced Cardiotoxicity by Paul Burridge, PhD, and Assistant Professor of Pharmacology at Northwestern

3rd webinar Pic.JPG
April 13, 2021
Surveillance for Cardiometabolic Disorders in Children and Adult Survivors of Childhood Cancers

Case presentation and Introduction of cardiac risk factors (20 mins)
Ming Hui Chen, MD, MMSc, FACC, FASE

Starting at the beginning - Components of metabolic syndrome and Cardiovascular risk factors in children who survived cancer (20 mins)
Julia Steinberger, MD, MS

Cardiovascular Risk factors and Cardiovascular disease screening in adults who survived childhood cancers - the IGHG CAD guideline (20 mins)
Dan Mulrooney, MD, MS

Impact of alteration in anti-cancer protocols over time, on decreasing CV risk and disease (20 mins)
Elizabeth (Lieke) A. M. Feijen, PhD

Webinar - December 16, 2020
Updates in Pediatric Cardiology


Steven Lipshultz, MD | Beginning with the End in Mind: Cardiotoxicity After Childhood Cancer


Thomas Ryan, MD, PhD | Cardio-Pulmonary Exercise Testing and Rehab in Cardio-Oncology


Steven Colan, MD, FACC, FASE | Differential Impact of Myocardial Mechanics in Acute Versus Late Doxorubicin Toxicity

bottom of page